450
Participants
Start Date
June 30, 2024
Primary Completion Date
December 30, 2026
Study Completion Date
December 31, 2027
Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）
"Drugs: Irinotecan Subjects in the control arm will receive irnotecan 150mg/m2 IV D1, D15, Q4W in 4-weeks cycles.~Drugs: Paclitaxel Subjects in the control arm will receive paclitaxel 80mg/m2 IV D1, D8, D15, Q4W in 4-week cycles, Drugs:FTD/TPI Subjects in the control arm will receive FTD/TPI 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (applicable in US/EU/Japan and other regions where FTD/TPI is approved for GC treatment)."
IBI343
Subjects in the experimental arm will receive IBI343 6mg/kg intravenous infusion (IV) D1, Q3W in 3-week cycles .
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
Shikoku Cancer Center, Matsuyama
RECRUITING
Gunma Prefectural Cancer Center, Ota-Shi
RECRUITING
Kure Medical Center And Chugoku Cancer Center, Kure
RECRUITING
Teine Keijinkai Hospital, Sapporo
RECRUITING
National Hospital Organization Kyushu Cancer Center, Fukuoka
RECRUITING
Hyogo Cancer Center, Akashi
RECRUITING
Kobe City Medical Center General Hospital, Kobe
RECRUITING
St. Marianna University Hospital, Kawasaki
RECRUITING
Yokohama City University Medical Center, Yokohama
RECRUITING
Kanagawa Cancer Center, Yokohama
RECRUITING
Kochi Health Sciences Center, Kochi
RECRUITING
Kindai University Hospital, Osakasayama-Shi
RECRUITING
The University of Osaka Hospital, Suita-shi
RECRUITING
Saitama Medical University - International Medical Center, Hidaka-Shi
RECRUITING
Saitama Prefectural Cancer Center, Kitaadachi-Gun
RECRUITING
Chiba Cancer Center, Chiba
RECRUITING
University of Tokyo Hospital, Bunkyō-Ku
RECRUITING
Tokyo Metropolitan Komagome Hospital, Bunkyō-Ku
RECRUITING
Cancer Institute Hospital of JFCR, Koto
RECRUITING
Gifu University Hospital, Gifu
RECRUITING
Osaka Prefectural Hospital Organization - Osaka International Cancer Institute, Osaka
Innovent Biologics (Suzhou) Co. Ltd.
INDUSTRY